Legal cultivation of cannabis gets a step closer

Published at Feb 10, 2016, in Features

Legislation allowing the cultivation of cannabis for the manufacture of therapeutic products hits parliament today – and it appears it has a great chance.

This morning health minister Susan Ley announced the introduction of legislation eight weeks in the making, describing it as the “missing piece” of medical cannabis legislation.

Amendments to the existing Narcotics Drugs Act are being pursued to allow the controlled cultivation of cannabis of medicinal or scientific purposes into a single unifying scheme – which would be a first for Australia.

At the moment there are provisions to allow the legal production and distribution of medical cannabis products, but there’s no single unifying scheme allowing for the cultivation of cannabis for therapeutic products.

Hence, Ley described it as a “missing piece”.

“For Australia, this is the missing piece in a patient’s journey,” Ley said in a statement.

“Importantly, having a safe, legal and reliable source of products will ensure medical practitioners are now at the centre of the decision making process on whether medicinal cannabis may be beneficial for their patient.”

It would appear that on a sentiment basis at least the legislation will enjoy bi-partisan support.

In 2014 a similar bill was introduced by the Greens but endorsed by both Liberal and Labor senators that would allow a national regulator – demonstrating that the issue has broad bi-partisan support.

Should the latest bill pass both houses, it would open the way for companies in the medical cannabis space to take more control of the supply chain within Australia.

Companies which would benefit include MMJ Phytotech (ASX:MMJ) and MGC Pharmaceuticals (ASX:MXC).

After merging with Canadian-based MMJ Bioscience last year MMJ is developing a range of CBD-based products aimed at the growing global market for medicinal cannabis, in partnership with a leading scientific research centre in Israel.

MMJ already has sold its first CBD-based pill via European distribution partners, with the sale taking place late last year.

MGC Pharmaceuticals (ASX:MXC) is aiming to produce high quality resins, oils, salves and creams made from CBD with growing operations in Slovenia and Namibia.

Last year, MXC became the first Australian registered company to gain permission to grow, process, import and export an unlimited quantity of Cannabis Sativa L (hemp) and its products.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Australian ASX Small Cap stocks | Why Finfeed.com is Australia’s leading small cap publication

Founded seven years ago, Finfeed.com is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise.

Finfeed.com provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more.

Finfeed.com is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!

X